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Sensitivity analysis confirmed the robustness of the model findings. 
CONCLUSIONS: This study shows that in Argentina, according to the model cost-
effectiveness results, abatacept with MTX would be dominant treatment option 
compared to infliximab and tocilizumab, for patients with rheumatoid arthritis 
after an inadequate response to MTX.  
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OBJECTIVES: Approximately 0.4% of the Latin American population over 16 years 
old is affected by Rheumatoid Arthritis (RA). RA has an important economic and 
social impact due to its chronic and progressive condition. The objective is to 
assess the cost-effectiveness (CE) of etanercept in the treatment for moderate to 
severe RA, among patients failing antirheumatic drugs, in comparison with the 
rest of anti-TNF and IL-6 blockers available in Honduras, from the health care 
payer’s perspective. METHODS: A decision-tree model was implemented to 
compare the costs and effectiveness of etanercept (comparator, 50mg/week), 
adalimumab (40mg/15 days), infliximab (3-10mg/kg), rituximab (1000mg day 0 
and 15, week 16-24) and tocilizumab (8mg/kg/month), all in combination with 
methotrexate, in the treatment of RA in adult population of Honduras. The 
effectiveness measures were: American College of Rheumatology (ACR) Response 
Criteria ACR<20 and ACR<70. Quality utilities were obtained from Health 
Assessment Questionnaire (HAQ). Local costs (2012 US$) were obtained from 
Official Social Security databases of Honduras. The outcomes were: total costs of 
RA (adverse events, exams and treatments) and QALYs gained. Univariate 
sensitivity analysis was performed. The time horizon was 2 years and the 
discount rate was 5% for costs and health outcomes. RESULTS: The total cost of 
etanercept was $US39,788.57, being $US1,149.43, $US3,131.82 $US6,622.29, and 
$US16,616.10 less expensive than tocilizumab, rituximab, adalimumab, and 
infliximab, respectively. Etanercept also gained the highest number of QALYs 
(1.5423) in comparison with adalimumab (1.5048), infliximab, (1.4299), rituximab 
(1.4674), and tocilizumab (1.4955). Cost-effectiveness analyses showed etanercept 
as the dominant strategy. Acceptability curves showed that at the willingness-
to-pay level of US$8,000/QALY, etanercept was cost-effective with a 100% 
probability. PSA results support the robustness of these findings. CONCLUSIONS: 
This is the first CE study for RA developed in Honduran population. Etanercept 
appeared as the most cost-effective alternative for RA compared to other anti-
TNF and IL-6 blockers.  
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OBJECTIVES: Administrative claims contain detailed medication, diagnosis, and 
procedure data, but their lack of clinical outcomes for rheumatoid arthritis (RA) 
has limited their use in comparative effectiveness research. A validated claims-
based algorithm uses adherence, dosing, and treatment modifications to 
estimate biologics’ effectiveness (low disease or remission) for RA. The objective 
was to implement this algorithm in a US managed-care database and calculate 
the cost per algorithm-defined responder among biologics approved for 
moderate to severe RA (etanercept, adalimumab, infliximab, golimumab, 
abatacept). METHODS: Data were obtained from the IMS PharMetrics Plus™ 
Database, comprised of adjudicated medical and pharmaceutical claims for 150 
million unique enrollees. The cohort included patients with RA aged 18-63, 
initiating treatment between January 2007 and December 2010, without RA 
biologics 6 months before first treatment, and enrolled between 6 months before 
and 12 months after first biologic. Other TNF responsive conditions were 
excluded. The algorithm defines lack of effectiveness as: medication possession 
ratio < 80% (or fewer infusions/injections than specified on US label), increase in 
biologic dose or frequency interval, switching biologics, adding new non-biologic 
Disease Modifying Anti-Rheumatic Drugs, glucocorticoid use, initiation or 
increase of glucocorticoid dose, or > 1 parenteral or intra-articular injection 
during the follow-up period. Drug and administration costs were obtained from 
allowed amounts on claims. RESULTS: The cohort included 16,011 patients, 
mean age 49.3, 76.7% female. Algorithm effectiveness (low disease or remission) 
criteria were met in 31.0% of etanercept (n=7,247), 28.6% of adalimumab 
(n=4,991), 20.2% of infliximab (n=2,352), 28.6% of abatacept (n=1,160), and 27.2% 
of golimumab (n=261) patients in the first 12 months of treatment. Mean first 
year cost per responder was lowest for etanercept ($50,141), followed by 
golimumab ($53,386), adalimumab ($56,941), abatacept ($73,516), and infliximab 
($114,089). CONCLUSIONS: Etanercept had the highest estimated effectiveness 
and lowest cost per responder among first-line RA biologics using a new, 
validated claims-based algorithm.  
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OBJECTIVES: Rheumatoid arthritis (RA) affects approximately 40,000 people in 
Costa Rica. It is associated with a significant effect on the patients’ quality of life 
and costs to society. The aim is to assess the cost-effectiveness of etanercept in 
the treatment for moderate to severe RA, among patients failing previous 
antirheumatic therapy (DMARDS), in comparison with the rest of anti-TNF and 
IL-6 blockers products in Costa Rica, from the health care payer’s perspective. 
METHODS: A decision tree model was used to compare the costs and 
effectiveness of the alternatives, all in combination with methotrexate, in the 
treatment of RA in adult population of Costa Rica. The alternatives included 
were: etanercept (comparator, 50mg/week), adalimumab (40mg/15 days), 
infliximab (3-10mg/kg), rituximab (1000mg day 0 and 15, week 16-24) and 
tocilizumab (8mg/kg/month). The effectiveness measures were: American 
College of Rheumatology (ACR) Response Criteria ACR<20 and ACR<70. Quality 
utilities were obtained from Health Assessment Questionnaire (HAQ). Local costs 
(2012 US$) were obtained from Costa Rica Social Security databases. The 
outcomes were expressed as total costs of RA and quality-adjusted life years 
(QALYs) gained. Univariate sensitivity analysis was performed. The time horizon 
was two years and the discount rate was 5% for costs and health outcomes. 
RESULTS: Results showed that etanercept gained the highest number of QALYs 
(1.5423) in comparison with adalimumab (1.5048), infliximab, (1.4299), rituximab 
(1.4674), and tocilizumab (1.4955). Etanercept appeared as the least expensive 
option (US$38,836.32) while infliximab resulted as the most expensive option 
(US$57,237.22). Cost-effectiveness analyses exhibited etanercept as the dominant 
strategy. Acceptability curves showed that at the willingness-to-pay level of 
US$10,000/QALY, Etanercept was cost-effective with a 100% probability. 
Probability sensitivity analysis results support the robustness of these findings. 
CONCLUSIONS: Etanercept is the most cost-effective alternative for treating RA 
among other anti-TNF and IL-6 blockers.  
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OBJECTIVES: Rheumatoid arthritis (RA) affects approximately 60.000 people in El 
Salvador. RA has a significant effect on quality of life of patients and it is 
associated with high costs to society. The objective is to assess the cost-
effectiveness (CE) of etanercept in the treatment for moderate to severe RA, 
among patients failing previous antirheumatic drugs (DMARDs), in comparison 
with the rest of anti-TNF and IL-6 blockers products available in El Salvador, 
from the health care payer’s perspective. METHODS: In order to compare the 
costs and effectiveness of the alternatives included, a decision-tree was utilized. 
The alternatives for treating RA were: etanercept (comparator, 50mg/week), 
adalimumab (40mg/15 days), infliximab (3-10mg/kg), rituximab (1000mg day 0 
and 15, week 16-24) and tocilizumab (8mg/kg/month), all in combination with 
methotrexate. The effectiveness measures were: American College of 
Rheumatology (ACR) Response Criteria ACR<20 and ACR<70. Quality utilities 
were obtained from Health Assessment Questionnaire (HAQ). Local costs (2012 
US$) were obtained from official databases from the Social Security of El 
Salvador. The outcomes were: total costs of RA and quality-adjusted life years 
(QALYs) gained. Univariate sensitivity analysis was performed. The time horizon 
was 1 year. RESULTS: Etanercept was the least expensive option ($US19,959.82) 
while infliximab was the most expensive option (US$25,262.66). The total cost for 
Adalimumab was $US21,236.14 and $21,301.85 for Rituximab. Etanercept gained 
the highest number of QALYs (0.79) compared to adalimumab (0.77), infliximab, 
(0.73), and rituximab (0.75). In the CE analyses, etanercept appeared as the 
dominant strategy. Acceptability curves showed that at the willingness-to-pay 
level of US$15,300/QALY, etanercept was cost effective with a 100% probability. 
Probability sensitivity analysis results support the robustness of these findings. 
CONCLUSIONS: Etanercept is the least expensive and most effective option for 
treating RA in El Salvador. Etanercept is cost-effective option according to <3 GDP 
per capita ($7,600; 2011) threshold of El Salvador.  
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Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for osteoarthritis 
(OA). All NSAIDs treatment carries gastrointestinal (GI) toxicity risk, ranging from 
mild dyspepsia to GI hemorrhage and perforation. Treatment with gastric 
mucosa protectors like potassium pump inhibitors (PPI) had been associated 
with long NSAID treatment to reduce GI toxicity. OBJECTIVES: To evaluate the 
cost-effectiveness and cost-utility of fixed-dose-combination (FDC) of 
naproxen/esomeprazole, NSAIDs or cyclooxygenase-2 inhibitors’ (COX-2) in 
chronic users at risk of gastropathy. METHODS: A Markov model was developed 
with a 3-month cycle during 1 year horizon. Health states represent adverse 
events (AE) GI and cardiovascular (CV); the risk of experiencing an AE and 
moving between different health states was taken from published clinical 
research. The model estimates the net impact of the treatment alternatives 
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available on the Mexican Formulary Catalog (naproxen/esomeprazole, NSAIDs 
group and celecoxib). Incremental cost-effectiveness ratio (ICER) was performed 
with two measures: Life Years without AE (LY) and Quality Adjusted Life Years 
(QALYs). The analysis was done from public perspective, only considered direct 
costs, and is reported in US dollars. RESULTS: Treatment with 
naproxen/esomeprazole versus NSAIDs represents an ICER of $318.85 for one 
year without AE; celecoxib had an ICER of $1,226.59, less effective than 
naproxen/esomeprazole. The ICER per QALY gain was $1,363.26 for 
naproxen/esomeprazole and $4,562.90 for celecoxib. Sensitivity analysis 
confirms the consistency of the results. CONCLUSIONS: Naproxen/esomeprazole 
FDC dominated celecoxib and NSAIDs. The use of naproxen/esomeprazole in the 
treatment of patients with OA at risk of developing GI AE is cost-effective and 
could be considered as the first option in an institutional setting.  
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OBJECTIVES: New Innovative Knee Implants (IKIs) have the potential to reduce 
patients' awareness of the artificial knee, increase their confidence in 
performing daily activities, and reduce problems leading to revisions compared 
with Contemporary Knee Implants (CKI). This study aimed to illustrate the 
expected economic value of a new IKI among osteoarthritis (OA) patients 
requiring total knee arthroplasty (TKA). METHODS: A Markov model was 
developed to explore the cost-effectiveness of the IKI compared with CKIs among 
OA patients undergoing TKA from a United States payer perspective. The model 
design distinguished between the IKI and CKIs in terms of functional status and 
implant survivorship. CKI survivorship was estimated using patient-level 
survivorship data with SIGMA fixed bearing knees from the United Kingdom 
National Joint Registry. To estimate IKI survivorship, the approach used by Suter 
et al. (2011) was adopted. Adjustments were made to the risk of revision for 
causes addressed in the design of the IKI, specifically, wear, loosening, pain, 
instability, patella maltracking, and stiffness. Costs and utilities associated with 
various health states were literature based. RESULTS: The model predicts that 
the IKI will reduce revisions by nearly 20% and that this improvement in 
survivorship will translate to economic savings. Additionally, independent of 
survivorship, improvements in patient functioning will result in economic value. 
The IKI is expected to be cost-neutral with improved health, when restricting the 
expected benefit to survivorship only, or to be a therapy that both improves 
health and reduces costs when functional improvements are also considered. 
CONCLUSIONS: Although TKA can be a successful intervention, there is still 
potential for IKIs to provide clinical and economic value. Further investigation to 
quantify the link between improvement in IKI design features and clinical 
outcomes is necessary to improve the understanding of potential IKI clinical and 
economic benefits.  
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OBJECTIVES: The aim of the study was to evaluate the cost-effectiveness of 
denosumab (60 mg every 6 months) in the treatment of postmenopausal 
osteoporosis (PMO) women in México at high risk of fractures and intolerant to 
oral bisphosphonates. METHODS: The study was conducted from the public 
payer perspective using the comparators of raloxifene (60 mg daily) and 
teriparatide (20 mcg daily). High risk was defined as having 2 of the following 3 
risk factors: Age ≥70 years, T-score ≤-3 or previous fracture. Life years gained 
(LYG) were the effectiveness measure used in the model. The model reported the 
weighted Incremental Cost-effectiveness Ratio (ICER) for 3 possible scenarios: 1) 
Age ≥70 years and T-score ≤-3, without previous fracture; 2) Age ≥ 70 years with 
previous fracture; 3) T-score ≤-3 with previous fracture. A Markov model was 
performed using a lifetime horizon and 5 years of treatment. The Diagnoses-
Related Groups costs reported by Mexican Institute for Social Security (IMSS) for 
Mexico were used for different types of fractures. A discount rate of 5% was used 
for costs and health outcomes. The costs were reported in 2011 Mexican pesos. 
RESULTS: According to the average results for the 3 scenarios, the costs are 
$199,546 pesos for raloxifene, $202,969 pesos for denosumab and $269,304 pesos 
for teriparatide. The incremental cost per LYG with denosumab in comparison 
with raloxifene is $42,775 Mexican pesos and $-941,995 Mexican pesos versus 
teriparatide. CONCLUSIONS: Denosumab is a cost-effective alternative versus 
raloxifene because the ICER is 22% below to 1 GDP per capita (local cost-
effectiveness threshold). Also, denosumab can be considered a cost-saving 
alternative versus teriparatide because it reduces costs and increases clinical 
benefits in the treatment of PMO women in Mexico at high risk for fracture and 
intolerant to oral BPs.  
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OBJECTIVES: Systemic idiopathic juvenile arthritis (sJIA) is a subtype of juvenile 
idiopathic arthritis (JIA), characterized by systemic manifestations of disease in 
addition to arthritis leading to significant patient morbidity, caregiver burden, 
and health care costs. The TENDER study demonstrated that treatment with 
tocilizumab resulted in a significant benefit over placebo. The objective of this 
study is to determine the cost-effectiveness of tocilizumab with or without 
methotrexate compared to placebo with methotrexate for the treatment of sJIA. 
METHODS: A Markov model was developed to capture time spent by patients in 
various health states, which included: no American College of Rheumatology 
(ACR) Response (uncontrolled), ACR Response 30, 50, 70, 90, and Death. Results 
were reported as incremental cost per additional quality adjusted life-years 
(QALY) gained, over a 16-year period (from age 2-18 years). Transition 
probabilities were derived from the TENDER study and published literature. The 
base case analysis focused on direct medical costs only from the perspective of 
the Canadian Ministry of Health (MoH). A second analysis was conducted from 
the societal perspective. Cost data were obtained from a variety of sources and 
reported as 2011 Canadian Dollars. A 5% discount rate was applied to both costs 
and patient outcomes. Multiple sensitivity analyses were undertaken to test the 
robustness of the model. RESULTS: From the MoH perspective, tocilizumab with 
or without methotrexate had an incremental cost-utility ratio (ICUR) of $69,787 
per additional QALY gained compared to placebo with methotrexate. The 
treatment with tocilizumab would be the dominant (less costly and more 
effective) treatment strategy from the societal perspective. Results were robust 
over a wide range of sensitivity analyses tested. CONCLUSIONS: Tocilizumab 
with or without methotrexate is a cost-effective strategy compared to placebo 
with methotrexate for patients with sJIA.  
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OBJECTIVES: This study determines the lifetime survival function, utility 
function and health care expenditure for 8 types of cancer, end-stage renal 
disease (ESRD) and rheumatoid arthritis (RA) stratified by gender and age in 
Taiwan, and provides data to estimate cost-per-QALY for comparison. 
METHODS: A total of 335,918 pathologically verified cancer patients registered in 
the National Cancer Registry of Taiwan during 1998-2007, and 125,277 ESRD 
patients and 39, 455 RA patients registered under “catastrophic illnesses” were 
included. All of them were followed until the end of 2010 to obtain the survival 
function, which were further extrapolated to lifetime based on a semi-
parametric method using the age- and sex-matched referents simulated from 
the life tables of the National Vital Statistics of Taiwan. The survival functions 
were adjusted using an EQ-5D utility value derived from a convenience sample of 
8,421 patients to estimate quality-adjusted life expectancies (QALE). The monthly 
health care expenditures attributable to different cancers, ESRD and RA were 
collected from the reimbursement database of the National Health Insurance 
(NHI). These values were multiplied by the corresponding survival probabilities 
to calculate the lifetime health care expenditure after adjusting consumer price 
indices for different calendar year up to 2010 and assumed a 3% discount rate 
later on. RESULTS: ESRD had the highest life-time health care expenditure and 
cost-per-QALY, followed by RA and cancers, which is 16,933 to 17,851 U.S. dollars 
(USD) of cost-per QALY, or about one GDP (gross domestic products) of Taiwan. 
Of the 8 different cancers studied, the lung cancer, esophagus cancer and liver 
cancer had the highest cost-per-QALY. There appears a trend of shorter life 
expectancy or QALY associated with higher cost-per-QALY. CONCLUSIONS: Such 
estimates of cost-effectiveness are an essential part on the consideration to 
accommodate new health technology in cancer and other chronic diseases 
control, including prevention.  
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OBJECTIVES: Oral glucocorticoids (OGCs) have therapeutic benefits in 
rheumatoid arthritis (RA), but can produce adverse effects. This study examined 
the association between rituximab adherence and OGC use reduction in RA 
patients. METHODS: Retrospective study using a large U.S. claims database. 
Patients included for study had initiated rituximab between March 1, 2006-March 
31, 2011 (initiation date=index), had pre-index exposure to anti-tumor necrosis 
factor-alpha (anti-TNF) therapy, were aged ≥18 years, had a medical claim with a 
diagnosis code for RA (ICD-9-CM 714.0x) between January 1, 2004-March 31, 2011, 
were continuously enrolled for 12 months before and ≥270 days after index, and 
had OGC use ≤30 days before index. Patients were excluded if they had medical 
claims with diagnosis codes for non-RA indications of biologic disease modifying 
antirheumatic drugs (BDMARDs). Based on rituximab infusion services dates and 
recommended 6-month reinfusions, rituximab exposure periods were 
constructed to start upon index and end at the first occurrence of switch to a 
